Analysts Advise Caution For Savient's Gout Drug
October 27, 2008 at 15:05 PM EDT
Analysts cited cardiovascular side effects to Savient Pharmaceuticals Inc.'s (Nasdaq: SVNT) gout treatment Puricase for advocating caution over the medication. The stock price skidded $8.64 to $2.94.
